• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Aziyo Biologics Inc. (Amendment)

    10/6/23 3:28:19 PM ET
    $AZYO
    Medical Specialities
    Health Care
    Get the next $AZYO alert in real time by email
    SC 13D/A 1 tm2327986d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Elutia Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    05479K106

    (CUSIP Number)

    W. Matthew Zuga

    36 Church Lane

    Westport, CT 06880

    (646) 793-3510

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    September 21, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Capital, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    48,931

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    48,931

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    48,931

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.3%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     1 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    53,818

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    53,818

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    53,818

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.3%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     2 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners QP, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    4,001,428

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    4,001,428

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,001,428

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    21.3%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     3 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners GP, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    4,813,673

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    4,813,673

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,813,673

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    25.6%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO (Limited Liability Company)

     

     4 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners GP, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    4,813,673

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    4,813,673

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,813,673

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    25.6%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     5 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Co-Investment Vehicle I, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    499,145

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    499,145

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    499,145

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.7%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO (Limited Liability Company)

     

     6 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Co-Investment Vehicle II, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    259,282

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    259,282

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    259,282

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.4%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO (Limited Liability Company)

     

     7 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Capital, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    48,931

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    48,931

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    48,931

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.3%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO (Limited Liability Company)

     

     8 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners II, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    86,613(1)

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    86,613(1)

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    86,613(1)

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.5%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)Includes: (a) 43,659 shares of Class A Common Stock directly owned, and (b) 42,954 shares of Class A Common Stock issuable upon exercise of Common Warrants purchased pursuant to that certain Securities Purchase Agreement, dated September 21, 2023.

     

     9 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners QP II, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    4,151,015(1)

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    4,151,015(1)

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,151,015(1)

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    22.1%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)Includes:(a) 2,092,392 shares of Class A Common Stock directly owned, and (b) 2,058,623 shares of Class A Common Stock issuable upon exercise of Common Warrants purchased pursuant to that certain Securities Purchase Agreement, dated September 21, 2023.

     

     10 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners GP II, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    7,827,821

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    7,827,821

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,827,821

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    41.7%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     11 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    HighCape Partners GP II, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    7,827,821

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    7,827,821

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,827,821

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    41.7%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO (Limited Liability Company)

     

     12 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Elutia PIPE Investment, LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware, United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    3,590,193(1)

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    3,590,193(1)

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,590,193(1)

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    19.1%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)Includes: (a) 1,436,077 shares of Class A Common Stock directly owned, and (b) 2,154,116 shares of Class A Common Stock issuable upon exercise of Common Warrants, purchased pursuant the Securities Purchase Agreement, dated September 21, 2023.

     

     13 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    W. Matthew Zuga

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    0

    8.

    SHARED VOTING POWER

     

    12,690,425

    9.

    SOLE DISPOSITIVE POWER

     

    0

    10.

    SHARED DISPOSITIVE POWER

     

    12,690,425

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,690,425

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    67.5%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     14 

     

     

    1.

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Kevin Rakin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a)        ¨

    (b)        ¨

    3. SEC USE ONLY

    4.

    SOURCE OF FUNDS (see instructions)

     

    OO

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7.

    SOLE VOTING POWER

     

    90,807

    8.

    SHARED VOTING POWER

     

    12,690,425

    9.

    SOLE DISPOSITIVE POWER

     

    90,807

    10.

    SHARED DISPOSITIVE POWER

     

    12,690,425

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,781,232

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (see instructions) ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    68.0%

    14.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     15 

     

     

    EXPLANATORY NOTES

     

    This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”) on December 8, 2021 (as amended, the “Schedule 13D”), relating to the shares of Class A Common Stock, par value $0.001 per share (the “Class A Common Stock”) of Elutia Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

     

    Item 2. Identity and Background.

     

    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    The Schedule 13D is being filed by the following persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

     

    HighCape Capital, L.P.

    HighCape Partners, L.P.

    HighCape Partners QP, L.P.

    HighCape Partners GP, LLC

    HighCape Partners GP, L.P.

    HighCape Co-Investment Vehicle I, LLC

    HighCape Co-Investment Vehicle II, LLC

    HighCape Capital, LLC

    HighCape Partners II, L.P.

    HighCape Partners QP II, L.P.

    HighCape Partners GP II, L.P.

    HighCape Partners GP II, LLC

    Elutia PIPE Investment, LP

    W. Matthew Zuga

    Kevin Rakin

     

    Each of the Reporting Persons, except for Messrs. Zuga and Rakin, is organized under the laws of the State of Delaware. Each of Messrs. Zuga and Rakin is a citizen of the United States. The principal business address of the Reporting Persons is 36 Church Lane, Westport, CT 06880. The Reporting Persons are principally engaged in the business of managing their investments in the securities of the Issuer.

     

    During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source or Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended and supplemented by inserting the following information at the end of Item 3:

     

    On September 21, 2023, in connection with the Issuer’s private placement, HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment LP purchased an aggregate of 2,837,128 Common Units (as defined below) from the Issuer at a purchase price of $1.4275 per Common Unit.

     

     16 

     

     

    The Reporting Persons obtained the funds used to acquire their interests in the Issuer’s securities through capital contributions from their partners and members.

     

    Item 4. Purpose of the Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented by inserting the following information at the end of Item 4:

     

    Purchase Agreement

     

    On September 21, 2023 (the “Closing Date”), pursuant to that certain Securities Purchase Agreement, dated as of September 18, 2023 (the “Purchase Agreement”), by and among HighCape Partners II, L.P., HighCape Partners QP II, L.P., Elutia PIPE Investment, LP, and certain other investors named therein (collectively, the “Investors”) and the Issuer, the Investors purchased an aggregate of 6,852,811 units (the “Common Units”) from the Issuer, each Common Unit comprised of (a) one share of the Issuer’s Class A common stock, par value $0.001 per share (“Class A Common Stock”) and (b) a warrant (a “Common Warrant”) to purchase one and one half shares of the Issuer’s Class A Common Stock (the “Offering”). The Common Units were sold at a purchase price of $1.4275 per unit. Each Common Warrant is exercisable at any time until the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the Issuer’s CanGaroo®RM antibiotic-eluting biologic envelope or (b) five years from the Closing Date, each at an exercise price per share of $1.4275. As a result of the Offering, (i) HighCape Partners II, L.P. acquired 28,636 shares of Class A Common Stock and 42,954 Common Warrants, (ii) HighCape Partners QP II, L.P. acquired 1,372,415 shares of Class A Common Stock and 2,058,623 Common Warrants, and (iii) Elutia PIPE Investment, LP acquired 1,436,077 shares of Class A Common Stock and 2,154,116 Common Warrants.

     

    Registration Rights Agreement

     

    On September 21, 2023, in connection with the Purchase Agreement, the Issuer and Investors entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Issuer agreed to prepare and file a registration statement with the SEC within 60 days after the Closing Date, for purposes of registering the resale of the Class A Common Stock issued in the Offering and the shares of Class A Common Stock issuable upon exercise of the Common Warrants issued in the Offering, and any shares of Class A Common Stock issued as a dividend or other distribution with respect to, in exchange for or in replacement of the Class A Common Stock or the Common Warrants. The Issuer agreed to use commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 90 days after the Closing Date, or 115 days after the Closing Date if the SEC reviews the registration statement.

     

    The foregoing descriptions of the Purchase Agreement and Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Purchase Agreement and Registration Rights Agreement, which are incorporated as Exhibit 2 and Exhibit 3 to this Amendment No. 2, respectively, and incorporated herein by reference.

     

     17 

     

     

    General

     

    The Reporting Persons acquired the securities described in this Amendment No. 2 for investment purposes and intend to review the investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

     

    The Reporting Persons, subject to certain provisions of the law, may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the board of directors, and stockholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Class A Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer’s business or corporate structure, including changes in management or the composition of the board of directors.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b)

     

    The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, based on 18,789,252 shares of Class A Common Stock outstanding as of September 21, 2023, as provided by the Issuer:

     

                   Shared   Sole power   Shared 
               Sole power   power to   to dispose   power to 
       Amount       to vote or   vote or to   or to direct   dispose or to 
       beneficially   Percent   to direct   direct the   the   direct the 
    Reporting Person  owned   of class   the vote   vote   disposition   disposition 
    HighCape Capital, L.P.   48,931    0.3%   0    48,931    0    48,931 
    HighCape Partners, L.P.   53,818    0.3%   0    53,818    0    53,818 
    HighCape Partners QP, L.P.   4,001,428    21.3%   0    4,001,428    0    4,001,428 
    HighCape Partners GP, LLC   4,813,673    25.6%   0    4,813,673    0    4,813,673 
    HighCape Partners GP, L.P.   4,813,673    25.6%   0    4,813,673    0    4,813,673 
    HighCape Co-Investment Vehicle I, LLC   499,145    2.7%   0    499,145    0    499,145 
    HighCape Co-Investment Vehicle II, LLC   259,282    1.4%   0    259,282    0    259,282 
    HighCape Capital, LLC   48,931    0.3%   0    48,931    0    48,931 
    HighCape Partners II, L.P.   86,613    0.5%   0    86,613    0    86,613 
    HighCape Partners QP II, L.P.   4,151,015    22.1%   0    4,151,015    0    4,151,015 
    HighCape Partners GP II, L.P.   7,827,821    41.7%   0    7,827,821    0    7,827,821 
    HighCape Partners GP II, LLC   7,827,821    41.7%   0    7,827,821    0    7,827,821 
    Elutia PIPE Investment, LP   3,590,193    19.1%   0    3,590,193    0    3,590,193 
    W. Matthew Zuga   12,690,425    67.5%   0    12,690,425    0    12,690,425 
    Kevin Rakin   12,781,232    68.0%   90,807    12,690,425    90,807    12,690,425 

     

     18 

     

     

    Kevin Rakin and W. Matthew Zuga are the managing members of HighCape Partners GP, LLC, which is the general partner of HighCape Partners GP, L.P., which is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. Messrs. Rakin and Zuga are the managing members of HighCape Capital, LLC, which is the general partner of HighCape Capital, L.P. Messrs. Rakin and Zuga are also the managing members of HighCape Partners GP II, LLC, which is the general partner of HighCape Partners GP II, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P.

     

    Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. Each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held of record by HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners II, L.P., HighCape Partners QP II, L.P., and Elutia PIPE Investment, LP.

     

    Mr. Rakin may be deemed to beneficially own the securities held of record by the Kevin L. Rakin Irrevocable Trust. Each of the Reporting Persons disclaims beneficial ownership of the securities held by the other Reporting Persons.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    The responses to Items 3, 4 and 5 and Exhibits 2 through 3 are hereby incorporated herein.

     

    Item 7. Material to Be Filed as Exhibits.

     

    Item 7 of the Statement is hereby further amended to add the following exhibits:

     

    Exhibit 1Joint Filing Agreement.
      
    Exhibit 2Securities Purchase Agreement, dated September 18, 2023, by and among Elutia Inc. and the Investors named therein (attached as Exhibit 10.1 to the Form 8-K filed by Elutia, Inc. on September 21, 2023 and incorporated herein by reference).
      
    Exhibit 3Registration Rights Agreement, dated September 21, 2023, by and among Elutia Inc. and the Investors named therein (attached as Exhibit 10.2 to the Form 8-K filed by Elutia Inc. on September 21, 2023 and incorporated herein by reference).

     

     19 

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 6, 2023

     

      HIGHCAPE CAPITAL, L.P.
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE PARTNERS, L.P.
       
      By: HighCape Partners GP, L.P., its general partner
      By: HighCape Partners GP, LLC, its general partner
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE PARTNERS QP, L.P.
       
      By: HighCape Partners GP, L.P., its general partner
      By: HighCape Partners GP, LLC, its general partner
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE PARTNERS GP, LLC
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE PARTNERS GP, L.P.
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member

     

     20 

     

     

      HIGHCAPE CO-INVESTMENT VEHICLE I, LLC
       
      By: HighCape Partners GP, L.P., its general partner
      By: HighCape Partners GP, LLC, its general partner
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE CO-INVESTMENT VEHICLE II, LLC
       
      By: HighCape Partners GP, L.P., its general partner
      By: HighCape Partners GP, LLC, its general partner
       
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
       
      HIGHCAPE CAPITAL, LLC
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
         
      HIGHCAPE PARTNERS II, L.P.
         
      By: HighCape Partners GP II, L.P., its general partner
      By: HighCape Partners GP II, LLC, its general partner
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member

     

     21 

     

     

      HIGHCAPE PARTNERS QP II, L.P.
         
      By: HighCape Partners GP II, L.P., its general partner
      By: HighCape Partners GP II, LLC, its general partner
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
         
      HIGHCAPE PARTNERS GP II, L.P.
         
      By: HighCape Partners GP II, LLC, its general partner
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
         
      HIGHCAPE PARTNERS GP II, LLC
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
         
      ELUTIA PIPE INVESTMENT, LP
         
      By: HighCape Partners GP II, L.P., its general partner
      By: HighCape Partners GP II, LLC, its general partner
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
      Title:   Managing Member
         
      By: /s/ W. Matthew Zuga
      Name: W. Matthew Zuga
         
      By: /s/ Kevin Rakin
      Name: Kevin Rakin

     

     22 

    Get the next $AZYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZYO

    DatePrice TargetRatingAnalyst
    3/4/2022$15.00 → $13.00Outperform
    Cowen & Co.
    More analyst ratings

    $AZYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mills C Randal

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:38:14 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Ferguson Matthew

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:35:23 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Williams Michelle Leroux

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:32:46 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen & Co. reiterated coverage on Aziyo Biologics with a new price target

      Cowen & Co. reiterated coverage of Aziyo Biologics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      3/4/22 9:16:21 AM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highcape Capital, Llc bought 2,837,128 shares (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      10/5/23 4:50:43 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Highcape Capital, L.P. bought 2,837,128 shares (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      10/5/23 4:43:44 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aziyo Biologics Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      2/14/24 4:51:40 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/7/24 6:55:18 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Aziyo Biologics Inc. (Amendment)

      SC 13D/A - ELUTIA INC. (0001708527) (Subject)

      1/9/24 4:17:26 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    SEC Filings

    See more
    • SEC Form 424B3 filed by Aziyo Biologics Inc.

      424B3 - ELUTIA INC. (0001708527) (Filer)

      2/14/24 4:40:48 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      2/2/24 4:30:21 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Aziyo Biologics Inc.

      S-8 - ELUTIA INC. (0001708527) (Filer)

      1/25/24 4:56:17 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors

      SILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. "David's impressive commercial expertise was vital in guiding some of the world's largest and most-well respected biopharmaceutical companies in achieving their growth milestones," said Dr. Randy Mills, Chief Executive Officer of Aziyo Biologics. "We specifically sought a Board member, like David, whose deep industry insights and busi

      10/24/22 8:00:00 AM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer

      SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. "Aziyo strives to have the best products in the markets in which we choose to compete, and Dr. Williams has the expertise and leadership to help us deliver just that," said Dr. Randy Mills, Chief Executive Officer. "Michelle has been a thought leader in regenerative medicine for two decades. She has a track record of consistently developing commercially successful products, including Osteocel®, the world's first stem cell product with cumulative sales of

      8/26/22 9:00:00 AM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Appoints Peter G. Edwards as General Counsel

      SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. "We are delighted to welcome such a strong and experienced leader as Peter to our executive team," said Ron Lloyd, President and Chief Executive Officer of Aziyo. "We expect his deep experience serving as general counsel to high growth companies, particularly in the healthcare sector, will prove to be invaluable as we head into our next phase of growth. We have

      8/31/21 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Financials

    Live finance-specific insights

    See more
    • Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

      Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. "Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company

      8/14/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

      SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID:

      7/31/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Reports Highest Sales and Gross Profit in Company History

      - All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Business Highlights: Net sales rose 14% compared to the prior-year period, to a record $13.1 million for first quarter 2023.Gross margin increased 11 percentage points year-over-year to 49%.Signed a partnership with LeMaitre Vascular to distribute Aziyo'

      5/10/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

      SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company's Events & Presentations webpage or by clicking here. A replay will be available on the Company's website following the event. Institutional investors interested in meeting with management during the conference may reach out

      9/8/23 8:30:00 AM ET
      $AZYO
      $ELUT
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

      – Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills

      9/6/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

      Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled "Rehabilitation of an Existing Device Implant Pocket Using a Biolog

      8/30/23 8:30:00 AM ET
      $AZYO
      Medical Specialities
      Health Care